Junto Health

juntohealth.org

At Junto Health, we believe that the healthcare ecosystem needs to adopt open innovation practices and co-development models to successfully implement, and scale, new technology. We also know that sometimes you need a little help from your friends, so we have curated an exclusive network of members representing the best providers, payors, tech companies, pharma, investors, policy advisors, and startups.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

BIOMARIN AND SKYLINE THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NOVEL GENE THERAPIES FOR CARDIOVASCULAR DISEASES

BioMarin Pharmaceutical Inc. | December 17, 2021

news image

BioMarin Pharmaceutical Inc. and Skyline Therapeutics a gene and cell therapy company focused on developing novel treatments for unmet medical needs, announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus gene therapies to treat genetic cardiovascular diseases. The partnership will leverage Skyline Therapeutics' integrated AAV gene therapy platform based on its proprietary vector engineer...

Read More

AKERS BIOSCIENCES AND PREMAS BIOTECH ANNOUNCE PROGRESS IN ITS VACCINE DEVELOPMENT FOR COVID-19

PipelineReview | April 06, 2020

news image

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate. The clone development process has four primary steps including first, the design and synthesis of the genes; second, the selecti...

Read More

Cell and Gene Therapy

TAYSHA GENE THERAPIES ANNOUNCES NEW ADDITIONS TO LEADERSHIP TEAM TO DEEPEN MANUFACTURING AND COMMUNICATIONS CAPABILITIES

Taysha | December 30, 2020

news image

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-driven gene therapy organization focused in on creating and commercializing AAV-based quality treatments for the treatment of monogenic infections of the focal sensory system in both uncommon and huge patient populaces, today reported new increases to its authority group with the arrangements of Greg Gara as Senior Vice President of Manufacturing and Kimberly Lee, D.O., as Senior Vice President of Corporate Communications and Investor Relatio...

Read More

MedTech, Industrial Impact

TWIST BIOSCIENCE ENTERS INTO THIRD COLLABORATION WITH ASTELLAS TO SUPPORT ANTIBODY DISCOVERY FOR IMMUNOTHERAPIES

Businesswire | April 21, 2023

news image

Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. by which Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for drug discovery and development. “We are pleased to extend our collaboration with Astellas to three agreements across two groups within the company, showcasing our ab...

Read More
news image

Cell and Gene Therapy

BIOMARIN AND SKYLINE THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NOVEL GENE THERAPIES FOR CARDIOVASCULAR DISEASES

BioMarin Pharmaceutical Inc. | December 17, 2021

BioMarin Pharmaceutical Inc. and Skyline Therapeutics a gene and cell therapy company focused on developing novel treatments for unmet medical needs, announced a multi-year global strategic collaboration for the discovery, development and commercialization of Adeno-Associated Virus gene therapies to treat genetic cardiovascular diseases. The partnership will leverage Skyline Therapeutics' integrated AAV gene therapy platform based on its proprietary vector engineer...

Read More
news image

AKERS BIOSCIENCES AND PREMAS BIOTECH ANNOUNCE PROGRESS IN ITS VACCINE DEVELOPMENT FOR COVID-19

PipelineReview | April 06, 2020

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate. The clone development process has four primary steps including first, the design and synthesis of the genes; second, the selecti...

Read More
news image

Cell and Gene Therapy

TAYSHA GENE THERAPIES ANNOUNCES NEW ADDITIONS TO LEADERSHIP TEAM TO DEEPEN MANUFACTURING AND COMMUNICATIONS CAPABILITIES

Taysha | December 30, 2020

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-driven gene therapy organization focused in on creating and commercializing AAV-based quality treatments for the treatment of monogenic infections of the focal sensory system in both uncommon and huge patient populaces, today reported new increases to its authority group with the arrangements of Greg Gara as Senior Vice President of Manufacturing and Kimberly Lee, D.O., as Senior Vice President of Corporate Communications and Investor Relatio...

Read More
news image

MedTech, Industrial Impact

TWIST BIOSCIENCE ENTERS INTO THIRD COLLABORATION WITH ASTELLAS TO SUPPORT ANTIBODY DISCOVERY FOR IMMUNOTHERAPIES

Businesswire | April 21, 2023

Twist Bioscience Corporation a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. by which Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for drug discovery and development. “We are pleased to extend our collaboration with Astellas to three agreements across two groups within the company, showcasing our ab...

Read More

Resources

resource image

Cell and Gene Therapy, Industrial Impact

GMP Grade PMSF and Protease Inhibitors

Whitepaper

resource image

Industrial Impact, Industry Outlook

Are Nitrosamines a Concern for Biologic Manufacturers?

Whitepaper

resource image

Industrial Impact

Bruker Services & Software

Video

resource image

Cell and Gene Therapy, Industrial Impact

GMP Grade PMSF and Protease Inhibitors

Whitepaper

resource image

Industrial Impact, Industry Outlook

Are Nitrosamines a Concern for Biologic Manufacturers?

Whitepaper

resource image

Industrial Impact

Bruker Services & Software

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us